Clinical outcome of pretreated B-cell chronic lymphocytic leukemia following alemtuzumab therapy: a retrospective study on various cytogenetic risk categories.
Fiegl, M. 1,*; Erdel, M. 2; Tinhofer, I. 3; Brychtova, Y. 4; Panovska, A. 4; Doubek, M. 4; Eigenberger, K. 5; Fonatsch, C. 6; Hopfinger, G. 7; Muhlberger, H. 7; Zabernigg, A. 8; Falkner, F. 1; Gastl, G. 1; Mayer, J. 4; Greil, R. 3; for The Austrian Collaborative Study Group on Alemtuzumab in Chronic Lymphocytic Leukemia, in cooperation with The Czech Leukemia Study Group for Life, CELL
Annals of Oncology.
21(12):2410-2419, December 2010.